News >

Updated Data Confirm Survival, QoL Benefit With Lutathera in GI NETs

Brandon Scalea
Published: Sunday, Sep 09, 2018

Jonathan Strosberg, MD

Jonathan Strosberg, MD
Lutathera (lutetium Lu 177 dotatate) continued to demonstrate a statistically meaningful progression-free survival (PFS) and quality-of-life (QoL) benefit in patients with midgut neuroendocrine tumors (NETs), according to updated data of the NETTER-1 trial presented at the 2018 ASCO Annual Meeting.

At the time the data were presented, the median overall survival (OS) for patients treated with Lutathera was not reached. Those treated with high-dose octreotide demonstrated a median OS of 27.4 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x